Evidence map›Paper›PMID 34637335›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Reply to J. Wei et al.

Nancy U Lin, Mark Pegram, Solmaz Sahebjam, Nuhad Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Whitney Kirschbrown, Priya Kumthekar

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Nancy U LinNancy U. Lin, MD, Dana-Farber Cancer Institute, Boston, MA; Mark Pegram, MD, Stanford Comprehensive Cancer Institute, Palo Alto, CA; Solmaz Sahebjam, MD, Moffitt Cancer Center, University of South Florida, Tampa, FL; Nuhad Ibrahim, MD, MD Anderson Cancer Center, Houston, TX; Anita Fung, PharmD, Anna Cheng, PharmD, Alan Nicholas, PhD, and Whitney Kirschbrown, PharmD, PhD, Genentech Inc., South San Francisco, CA; and Priya Kumthekar, MD, Northwestern University, Chicago, IL.ORCID 0000-0003-2263-5413
Mark PegramNancy U. Lin, MD, Dana-Farber Cancer Institute, Boston, MA; Mark Pegram, MD, Stanford Comprehensive Cancer Institute, Palo Alto, CA; Solmaz Sahebjam, MD, Moffitt Cancer Center, University of South Florida, Tampa, FL; Nuhad Ibrahim, MD, MD Anderson Cancer Center, Houston, TX; Anita Fung, PharmD, Anna Cheng, PharmD, Alan Nicholas, PhD, and Whitney Kirschbrown, PharmD, PhD, Genentech Inc., South San Francisco, CA; and Priya Kumthekar, MD, Northwestern University, Chicago, IL.ORCID 0000-0002-9743-8118
Solmaz SahebjamNancy U. Lin, MD, Dana-Farber Cancer Institute, Boston, MA; Mark Pegram, MD, Stanford Comprehensive Cancer Institute, Palo Alto, CA; Solmaz Sahebjam, MD, Moffitt Cancer Center, University of South Florida, Tampa, FL; Nuhad Ibrahim, MD, MD Anderson Cancer Center, Houston, TX; Anita Fung, PharmD, Anna Cheng, PharmD, Alan Nicholas, PhD, and Whitney Kirschbrown, PharmD, PhD, Genentech Inc., South San Francisco, CA; and Priya Kumthekar, MD, Northwestern University, Chicago, IL.
Nuhad IbrahimNancy U. Lin, MD, Dana-Farber Cancer Institute, Boston, MA; Mark Pegram, MD, Stanford Comprehensive Cancer Institute, Palo Alto, CA; Solmaz Sahebjam, MD, Moffitt Cancer Center, University of South Florida, Tampa, FL; Nuhad Ibrahim, MD, MD Anderson Cancer Center, Houston, TX; Anita Fung, PharmD, Anna Cheng, PharmD, Alan Nicholas, PhD, and Whitney Kirschbrown, PharmD, PhD, Genentech Inc., South San Francisco, CA; and Priya Kumthekar, MD, Northwestern University, Chicago, IL.ORCID 0000-0001-8660-243X
Anita FungNancy U. Lin, MD, Dana-Farber Cancer Institute, Boston, MA; Mark Pegram, MD, Stanford Comprehensive Cancer Institute, Palo Alto, CA; Solmaz Sahebjam, MD, Moffitt Cancer Center, University of South Florida, Tampa, FL; Nuhad Ibrahim, MD, MD Anderson Cancer Center, Houston, TX; Anita Fung, PharmD, Anna Cheng, PharmD, Alan Nicholas, PhD, and Whitney Kirschbrown, PharmD, PhD, Genentech Inc., South San Francisco, CA; and Priya Kumthekar, MD, Northwestern University, Chicago, IL.
Anna ChengNancy U. Lin, MD, Dana-Farber Cancer Institute, Boston, MA; Mark Pegram, MD, Stanford Comprehensive Cancer Institute, Palo Alto, CA; Solmaz Sahebjam, MD, Moffitt Cancer Center, University of South Florida, Tampa, FL; Nuhad Ibrahim, MD, MD Anderson Cancer Center, Houston, TX; Anita Fung, PharmD, Anna Cheng, PharmD, Alan Nicholas, PhD, and Whitney Kirschbrown, PharmD, PhD, Genentech Inc., South San Francisco, CA; and Priya Kumthekar, MD, Northwestern University, Chicago, IL.ORCID 0000-0001-7300-3067
Alan NicholasNancy U. Lin, MD, Dana-Farber Cancer Institute, Boston, MA; Mark Pegram, MD, Stanford Comprehensive Cancer Institute, Palo Alto, CA; Solmaz Sahebjam, MD, Moffitt Cancer Center, University of South Florida, Tampa, FL; Nuhad Ibrahim, MD, MD Anderson Cancer Center, Houston, TX; Anita Fung, PharmD, Anna Cheng, PharmD, Alan Nicholas, PhD, and Whitney Kirschbrown, PharmD, PhD, Genentech Inc., South San Francisco, CA; and Priya Kumthekar, MD, Northwestern University, Chicago, IL.
Whitney KirschbrownNancy U. Lin, MD, Dana-Farber Cancer Institute, Boston, MA; Mark Pegram, MD, Stanford Comprehensive Cancer Institute, Palo Alto, CA; Solmaz Sahebjam, MD, Moffitt Cancer Center, University of South Florida, Tampa, FL; Nuhad Ibrahim, MD, MD Anderson Cancer Center, Houston, TX; Anita Fung, PharmD, Anna Cheng, PharmD, Alan Nicholas, PhD, and Whitney Kirschbrown, PharmD, PhD, Genentech Inc., South San Francisco, CA; and Priya Kumthekar, MD, Northwestern University, Chicago, IL.ORCID 0000-0003-0580-5425
Priya KumthekarNancy U. Lin, MD, Dana-Farber Cancer Institute, Boston, MA; Mark Pegram, MD, Stanford Comprehensive Cancer Institute, Palo Alto, CA; Solmaz Sahebjam, MD, Moffitt Cancer Center, University of South Florida, Tampa, FL; Nuhad Ibrahim, MD, MD Anderson Cancer Center, Houston, TX; Anita Fung, PharmD, Anna Cheng, PharmD, Alan Nicholas, PhD, and Whitney Kirschbrown, PharmD, PhD, Genentech Inc., South San Francisco, CA; and Priya Kumthekar, MD, Northwestern University, Chicago, IL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34637335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.